Top Medical News
13 hours ago
The Erection Hardness Scale (EHS) proves to be reliable in differentiating between predominantly organic and apparently nonorganic erectile dysfunction (ED), reducing the need for further nocturnal penile tumescence and rigidity (NPTR) testing, as reported in a study.
Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.
Most men with a history of anabolic steroid use have severe oligospermia, with only a few of them achieving normal semen parameters after 6 months of treatment, according to a study.
2 days ago
Noninvasive urothelial papillary lesions of the bladder with an inverted growth pattern appear to have a low chance of recurrence and are associated with better outcomes, suggests a study.
Stephen Padilla, 2 days ago
Higher blood concentrations of heavy metals appear to contribute to chronic kidney disease (CKD), while elevated levels of plasma selenium and serum zinc reduce CKD risk, according to a Singapore study.
6 days ago
Treatment with electrofulguration for antibiotic-refractory recurrent urinary tract infections (UTI) demonstrates durable clinical cure and improvement over 5 years in menopausal women, reducing the need for long-term antibiotics, a study has shown.
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
Elvira Manzano, 17 May 2023
Whatever choice of therapy men with localized prostate cancer may have initially— surgery, radiation, or active monitoring — they would likely have a good 15-year outcome as shown in the ProtecT* trial.
Jairia Dela Cruz, 27 Apr 2023
Men who are considering vasectomy can rest easy knowing that the procedure has no harmful effect on their sexual health, as suggested in a study presented at EAU 2023.
Audrey Abella, 27 Apr 2023
In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.
Jairia Dela Cruz, 26 Apr 2023
Injecting a degradable hydrogel into the vas deferens appears to be a feasible means of birth control for men, leading to sperm-free semen within only 30 days of implantation with a low potential for harm, according to the initial results of a first-in-human clinical trial presented at EAU 2023.
Elvira Manzano, 24 Apr 2023
A simple urine test looking at genetic mutations in DNA predicts urothelial cancer – the most common type of bladder cancer – 12 years before patients develop symptoms in a recent study.
Stephen Padilla, 18 Apr 2023
Immunotherapy with MV-140 (Uromune) successfully prevents urinary tract infections (UTIs) in patients suffering from recurrent UTIs, suggest the results of a prospective study presented at the 38th Annual EAU Congress (EAU 2023).
Stephen Padilla, 17 Apr 2023
In patients undergoing transrectal ultrasound-guided prostate biopsy, prophylaxis with either fosfomycin or cefixime leads to fewer infectious complications, as shown in a study presented at the 38th Annual EAU Congress (EAU 2023).